Leading Liquid Biopsy Company, Exosome Diagnostics, Appoints John Boyce As Chief Executive Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exosome Diagnostics, the developer of a leading liquid biopsy platform that enables non-invasive diagnosis of disease states, potentially obviating the need for tissue biopsy, has announced the appointment of John Boyce as its Chief Executive Officer.

"I am delighted that John, a successful leader with a proven track record of starting and growing companies to the IPO or acquisition stage, has agreed to join Exosome Diagnostics"

"I am delighted that John, a successful leader with a proven track record of starting and growing companies to the IPO or acquisition stage, has agreed to join Exosome Diagnostics," stated Kapil Dhingra, Chairman of the Board of Directors of Exosome Diagnostics. Dr. Dhingra continued, "John's dynamism and extensive commercial experience will advance Exosome Diagnostics to its next inflection point, ushering in a new paradigm of non-invasive diagnostic tests which we believe can dramatically improve patient outcomes."

"On behalf of the Board, I wish to sincerely thank Tom McLain, who led the company as CEO over the past year and laid the foundation that has allowed the company to make significant strides in developing its platform and demonstrating its utility to address clinically important problems. I am delighted that Tom will continue with the company and will help to contribute to its future growth and success," stated Dr. Dhingra.

Mr. Boyce is an energetic leader and serial entrepreneur who has successfully raised over $100MM in funding from venture capital and private investors. Most recently, Mr. Boyce was the CEO of GnuBIO, Inc., a desktop DNA sequencing company that he co-founded in January 2011. Mr. Boyce raised a total of $18MM over two rounds of investor funding, and based on the clinical strategy and product roll-out initiative that he put in place, GnuBIO was acquired by Bio-Rad in April 2014 for a deal valued at up to $110MM. Prior to GnuBIO, Mr. Boyce started and sold Affomix, a digital proteomics company, to Illumina resulting in a significant return on investment for investors and shareholders within two years. Through the course of his career, he served in key positions in numerous life sciences companies to drive them either towards an acquisition or an IPO. Mr. Boyce also conceived, founded, and ran the Consumer Genetics Conference, which was acquired by Cambridge Healthtech Institute in 2012. In 2013, Mr. Boyce was awarded the honor as one of the top 15 technology luminaries in Massachusetts by the Boston Business Journal and Mass High Technology. In 2014, Mr. Boyce was made a Fellow at Harvard University and co-teaches "Innovation in Science and Engineering" (ES-139).

"I am excited and honored to be a part of Exosome Diagnostics, a leading company in the liquid biopsy space. The advancements over the last few years in genomic readout technology have resulted in tools that will enable rapid answers from genetic material in clinical settings. One of the last key pieces of the puzzle, from a patient perspective, is the procurement of patient starting material – which very often involves a biopsy. More importantly, it has become increasingly obvious that even when it is available, a tissue biopsy may not represent the totality of a patient's disease and can miss important clinically actionable mutations. This has greatly limited the advancement of personalized medicine," stated Mr. Boyce. "Exosome Diagnostics has developed an innovative platform that can capture significant amounts of exosomal RNA and cell free DNA from blood, in one step, thus potentially obviating the need for a biopsy for genetic interrogation and, frequently, proving more actionable genetic information that is possible with a biopsy. I believe that Exosome's platform, and the diagnostic tests that result from it, will not only improve disease monitoring but also lead to the administration of the right treatment for the right patient at the right time. Additionally, these tests could also lead to the screening of seemingly healthy patients, thereby enabling diagnosis of disease at its earliest stages and dramatically improving treatment outcome," stated Mr. Boyce.

Exosome Diagnostics has developed an innovative technology to capture both exosomal RNA and cell free DNA in one step, thus greatly enhancing the diagnostic accuracy over cell free DNA in isolation. The company is developing a portfolio of validated diagnostic tests that it will commercialize and work with the appropriate regulatory agencies for approval.

About Exosome Diagnostics

Exosome Diagnostics is a privately held company focused on developing and commercializing revolutionary biofluid-based diagnostics to deliver personalized precision healthcare that improves lives. The company's novel exosome-based technology platform, ExoLution™, can yield comprehensive and dynamic molecular insights to transform how cancer and other serious diseases are detected, diagnosed, treated and monitored. Visit www.exosomedx.com to learn more.

Exosome Diagnostics and ExoLution are registered and unregistered trademarks of Exosome Diagnostics, Inc.


Feinstein Kean Healthcare
Liz Melone, 617-256-6622
[email protected]